Literature DB >> 33291725

TRPM Channels in Human Diseases.

Ivanka Jimenez1,2, Yolanda Prado1,2, Felipe Marchant1,2, Carolina Otero3, Felipe Eltit4,5, Claudio Cabello-Verrugio1,6,7, Oscar Cerda2,8, Felipe Simon1,2,7.   

Abstract

The transient receptor potential melastatin (TRPM) subfamily belongs to the TRP cation channels family. Since the first cloning of TRPM1 in 1989, tremendous progress has been made in identifying novel members of the TRPM subfamily and their functions. The TRPM subfamily is composed of eight members consisting of four six-transmembrane domain subunits, resulting in homomeric or heteromeric channels. From a structural point of view, based on the homology sequence of the coiled-coil in the C-terminus, the eight TRPM members are clustered into four groups: TRPM1/M3, M2/M8, M4/M5 and M6/M7. TRPM subfamily members have been involved in several physiological functions. However, they are also linked to diverse pathophysiological human processes. Alterations in the expression and function of TRPM subfamily ion channels might generate several human diseases including cardiovascular and neurodegenerative alterations, organ dysfunction, cancer and many other channelopathies. These effects position them as remarkable putative targets for novel diagnostic strategies, drug design and therapeutic approaches. Here, we review the current knowledge about the main characteristics of all members of the TRPM family, focusing on their actions in human diseases.

Entities:  

Keywords:  TRPM channels; human diseases; ion channels

Mesh:

Substances:

Year:  2020        PMID: 33291725      PMCID: PMC7761947          DOI: 10.3390/cells9122604

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  374 in total

1.  Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity.

Authors:  H Yamaguchi; M Matsushita; A C Nairn; J Kuriyan
Journal:  Mol Cell       Date:  2001-05       Impact factor: 17.970

2.  Transient receptor potential channels in essential hypertension.

Authors:  Daoyan Liu; Alexandra Scholze; Zhiming Zhu; Katharina Krueger; Florian Thilo; Antje Burkert; Katrin Streffer; Stefan Holz; Christian Harteneck; Walter Zidek; Martin Tepel
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

3.  Promiscuous G-Protein-Coupled Receptor Inhibition of Transient Receptor Potential Melastatin 3 Ion Channels by Gβγ Subunits.

Authors:  Omar Alkhatib; Robson da Costa; Clive Gentry; Talisia Quallo; Stuart Bevan; David A Andersson
Journal:  J Neurosci       Date:  2019-08-26       Impact factor: 6.167

4.  Triphenylphosphine oxide is a potent and selective inhibitor of the transient receptor potential melastatin-5 ion channel.

Authors:  R Kyle Palmer; Karnail Atwal; Ivona Bakaj; Stacy Carlucci-Derbyshire; M Tulu Buber; Rok Cerne; Rosa Y Cortés; Heather R Devantier; Vincent Jorgensen; Aaron Pawlyk; S Paul Lee; Dennis G Sprous; Zheng Zhang; Robert Bryant
Journal:  Assay Drug Dev Technol       Date:  2010-12       Impact factor: 1.738

Review 5.  Flufenamic acid as an ion channel modulator.

Authors:  Romain Guinamard; Christophe Simard; Christopher Del Negro
Journal:  Pharmacol Ther       Date:  2013-01-25       Impact factor: 12.310

Review 6.  Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma.

Authors:  Zachary A Bacigalupa; W Kimryn Rathmell
Journal:  Cancer Lett       Date:  2020-06-05       Impact factor: 8.679

7.  Stimulation of transient receptor potential M3 (TRPM3) channels increases interleukin-8 gene promoter activity involving AP-1 and extracellular signal-regulated protein kinase.

Authors:  Sandra Rubil; Andrea Lesch; Naofumi Mukaida; Gerald Thiel
Journal:  Cytokine       Date:  2017-10-02       Impact factor: 3.861

Review 8.  TRPM2: a candidate therapeutic target for treating neurological diseases.

Authors:  Jillian Corinne Belrose; Michael Frederick Jackson
Journal:  Acta Pharmacol Sin       Date:  2018-04-19       Impact factor: 6.150

9.  De novo substitutions of TRPM3 cause intellectual disability and epilepsy.

Authors:  David A Dyment; Paulien A Terhal; Cecilie F Rustad; Kristian Tveten; Christopher Griffith; Parul Jayakar; Marwan Shinawi; Sara Ellingwood; Rosemarie Smith; Koen van Gassen; Kirsty McWalter; A Micheil Innes; Matthew A Lines
Journal:  Eur J Hum Genet       Date:  2019-07-05       Impact factor: 4.246

10.  9-Phenanthrol, a TRPM4 inhibitor, protects isolated rat hearts from ischemia-reperfusion injury.

Authors:  Jing Wang; Ken Takahashi; Hulin Piao; Peng Qu; Keiji Naruse
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

View more
  14 in total

1.  The crystal structure of TRPM2 MHR1/2 domain reveals a conserved Zn2+ -binding domain essential for structural integrity and channel activity.

Authors:  Simon Sander; Jelena Pick; Ellen Gattkowski; Ralf Fliegert; Henning Tidow
Journal:  Protein Sci       Date:  2022-06       Impact factor: 6.993

2.  The Antibody Receptor Fc Gamma Receptor IIIb Induces Calcium Entry via Transient Receptor Potential Melastatin 2 in Human Neutrophils.

Authors:  Omar Rafael Alemán; Nancy Mora; Carlos Rosales
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

Review 3.  TRP Channels as Sensors of Aldehyde and Oxidative Stress.

Authors:  Katharina E M Hellenthal; Laura Brabenec; Eric R Gross; Nana-Maria Wagner
Journal:  Biomolecules       Date:  2021-09-24

Review 4.  Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review.

Authors:  Stanley Du Preez; Helene Cabanas; Donald Staines; Sonya Marshall-Gradisnik
Journal:  Int J Environ Res Public Health       Date:  2021-10-12       Impact factor: 3.390

5.  Perillaldehyde improves cognitive function in vivo and in vitro by inhibiting neuronal damage via blocking TRPM2/NMDAR pathway.

Authors:  Yue Qiu; Xian-Jun Xue; Geng Liu; Miao-Miao Shen; Chun-Yan Chao; Jie Zhang; Ya-Qi Guo; Qian-Qian Niu; Ya-Nan Yu; Yu-Ting Song; Huan-Huan Wang; Shuang-Xi Wang; Yu-Jing Chen; Lin-Hua Jiang; Peng Li; Ya-Ling Yin
Journal:  Chin Med       Date:  2021-12-13       Impact factor: 5.455

6.  Refractory hypokalemia caused by cetuximab with advanced colorectal cancer patients: the case series and literature review.

Authors:  Yun-Wang Chen; Min Yang; Ming-Xing Wang; Jia-Hong Jiang; Ding-Yi Jiang; Zhe-Ling Chen; Liu Yang
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

Review 7.  The Roles of Transient Receptor Potential Ion Channels in Pathologies of Glaucoma.

Authors:  Lin Ma; Xin Liu; Qing Liu; Sen Jin; Heng Chang; Haixia Liu
Journal:  Front Physiol       Date:  2022-02-03       Impact factor: 4.566

Review 8.  On the Connections between TRPM Channels and SOCE.

Authors:  Guilherme H Souza Bomfim; Barbara A Niemeyer; Rodrigo S Lacruz; Annette Lis
Journal:  Cells       Date:  2022-04-01       Impact factor: 6.600

Review 9.  Pharmacological Modulation and (Patho)Physiological Roles of TRPM4 Channel-Part 2: TRPM4 in Health and Disease.

Authors:  Csaba Dienes; Zsigmond Máté Kovács; Tamás Hézső; János Almássy; János Magyar; Tamás Bányász; Péter P Nánási; Balázs Horváth; Norbert Szentandrássy
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-28

Review 10.  Pharmacological Modulation and (Patho)Physiological Roles of TRPM4 Channel-Part 1: Modulation of TRPM4.

Authors:  Zsigmond Máté Kovács; Csaba Dienes; Tamás Hézső; János Almássy; János Magyar; Tamás Bányász; Péter P Nánási; Balázs Horváth; Norbert Szentandrássy
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.